A carregar...
Long-Term Daclizumab Therapy in Relapsing—Remitting Multiple Sclerosis
We performed a retrospective review of side effects and clinical outcomes in relapsing—remitting (RR) multiple sclerosis (MS) patients receiving long-term treatment with daclizumab. Twelve patients with RR MS were initially treated with daclizumab at 1 mg/kg IV, again 14 days later and then monthly...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3002600/ https://ncbi.nlm.nih.gov/pubmed/21180619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285609337992 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|